» Articles » PMID: 36291884

Evolution of Head and Neck Cutaneous Squamous Cell Carcinoma Nodal Staging-An Australian Perspective

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Oct 27
PMID 36291884
Authors
Affiliations
Soon will be listed here.
Abstract

Cutaneous squamous cell carcinoma of the head and neck (HNcSCC) is one of the commonest malignancies. When patients present with regional metastatic disease, treatment escalation results in considerable morbidity and survival is markedly reduced. Owing to the high incidence, Australian institutions have been at the forefront of advocating for reliable, accurate, and clinically useful staging systems that recognise the distinct biological characteristics of HNcSCC. As a result, an extensive body of literature has been produced over the past two decades, which has defined critical prognostic factors, critiqued existing staging systems, and proposed alternative staging models. Notwithstanding, a suitable staging system has proved elusive. The goal of cancer staging is to group patients according to cancer characteristics for which differs between groups (distinctiveness), consistently decreases with increasing stage (monotonicity), and is similar within a group (homogeneity). Despite implementing major changes based on published data, the latest edition of the American Joint Committee on Cancer (AJCC) staging manual fails to satisfy these fundamental requirements. This review chronologically explores and summarises the Australian contribution to prognostication and nodal staging of HNcSCC and highlights the ongoing challenges.

Citing Articles

Immunosuppression and Outcomes in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck.

Iancu D, Fulga A, Vesa D, Fulga I, Tutunaru D, Zenovia A Clin Pract. 2025; 15(1).

PMID: 39851804 PMC: 11764338. DOI: 10.3390/clinpract15010021.


Metastatic patterns and treatment options for head and neck cutaneous squamous cell carcinoma (Review).

Iancu D, Fulga A, Vesa D, Zenovia A, Fulga I, Sarbu M Mol Clin Oncol. 2024; 20(6):40.

PMID: 38756868 PMC: 11097132. DOI: 10.3892/mco.2024.2739.


Metastatic cutaneous squamous cell carcinoma accounts for nearly all squamous cell carcinomas of the parotid gland.

Bradley P, Stenman G, Thompson L, Skalova A, Simpson R, Slootweg P Virchows Arch. 2024; 485(1):3-11.

PMID: 38630141 PMC: 11271436. DOI: 10.1007/s00428-024-03798-5.


Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck: A Review.

Desai N, Divatia M, Jadhav A, Wagh A Curr Oncol. 2023; 30(7):6634-6647.

PMID: 37504347 PMC: 10378287. DOI: 10.3390/curroncol30070487.

References
1.
Ebrahimi A, Clark J, Ahmadi N, Palme C, Morgan G, Veness M . Prognostic significance of disease-free interval in head and neck cutaneous squamous cell carcinoma with nodal metastases. Head Neck. 2012; 35(8):1138-43. DOI: 10.1002/hed.23096. View

2.
Greene F, Sobin L . The staging of cancer: a retrospective and prospective appraisal. CA Cancer J Clin. 2008; 58(3):180-90. DOI: 10.3322/CA.2008.0001. View

3.
Porceddu S, Bressel M, Poulsen M, Stoneley A, Veness M, Kenny L . Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial. J Clin Oncol. 2018; 36(13):1275-1283. DOI: 10.1200/JCO.2017.77.0941. View

4.
Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope F . Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discov. 2020; 10(12):1808-1825. PMC: 7710563. DOI: 10.1158/2159-8290.CD-20-0522. View

5.
Vasan K, Hubert Low T, Gupta R, Ashford B, Asher R, Gao K . Lymph node ratio as a prognostic factor in metastatic cutaneous head and neck squamous cell carcinoma. Head Neck. 2018; 40(5):993-999. DOI: 10.1002/hed.25066. View